4.5 Article

Pattern of regional white matter hyperintensity volume in mild cognitive impairment subtypes and associations with decline in daily functioning

期刊

NEUROBIOLOGY OF AGING
卷 86, 期 -, 页码 134-142

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.neurobiolaging.2019.10.016

关键词

Mild cognitive impairment; MCI subtypes; White matter hyperintensity; Cerebrovascular disease; Neuropsychology; Daily functioning

资金

  1. VA Clinical Science Research & Development (Career Development Award-2) [1IK2CX000938, 1IK2CX001415]
  2. Alzheimer's Association [AARF-17-528918, AARG-18-566254, AARG-17-500358]
  3. National Institutes of Health (National Institute on Aging) [R01 AG049810, K24 AG026431]
  4. National Institutes of Health (San Diego State University Advancing Diversity in Aging Research Program) [R25AG043364]
  5. Dana Foundation
  6. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
  7. DOD ADNI (Department of Defense) [W81XWH-12-2e0012]
  8. National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering
  9. AbbVie, Alzheimer's Association
  10. Alzheimer's Drug Discovery Foundation
  11. Araclon Biotech
  12. BioClinica, Inc
  13. Biogen
  14. Bristol-Myers Squibb Company
  15. CereSpir, Inc
  16. Cogstate
  17. Eisai Inc
  18. Elan Pharmaceuticals, Inc
  19. Eli Lilly and Company
  20. EuroImmun
  21. F. Hoffmann-La Roche Ltd
  22. Genentech, Inc
  23. Fujirebio
  24. GE Healthcare
  25. IXICO Ltd
  26. Janssen Alzheimer Immunotherapy Research & Development, LLC.
  27. Johnson & Johnson Pharmaceutical Research & Development LLC.
  28. Lumosity
  29. Lundbeck
  30. Merck Co, Inc
  31. Meso Scale Diagnostics, LLC.
  32. NeuroRx Research
  33. Neurotrack Technologies
  34. Novartis Pharmaceuticals Corporation
  35. Pfizer Inc
  36. Piramal Imaging
  37. Servier
  38. Takeda Pharmaceutical Company
  39. Transition Therapeutics
  40. Canadian Institutes of Health Research

向作者/读者索取更多资源

White matter hyperintensities (WMHs), a marker of small-vessel cerebrovascular disease, increase risk for mild cognitive impairment (MCI). Less is known about whether regional WMHs distinguish MCI subtypes and predict decline in everyday functioning. About 618 Alzheimer's Disease Neuroimaging Initiative participants (301 cognitively normal [CN]; 232 amnestic MCI [aMCI]; 85 nonamnestic MCI [naMCI]) underwent neuropsychological testing, MRI, and assessment of everyday functioning. aMCI participants showed greater temporal (p = 0.002) and occipital WMHs (p = 0.030) relative to CN whereas naMCI participants had greater frontal (p = 0.045), temporal (p = 0.003), parietal (p = 0.018), and occipital (p < 0.001) WMH compared with CN. Relative to those with aMCI, individuals with naMCI showed greater occipital WMH (p = 0.013). Greater WMH in temporal (p = 0.001) and occipital regions (p = 0.006) was associated with faster decline in everyday functioning across the sample. Temporal lobe WMHs were disproportionately associated with accelerated functional decline among naMCI (p = 0.045). Regional WMH volumes vary across cognitive groups and predict functional decline. Cerebrovascular markers may help identify individuals at risk for decline and distinguish subtypes of cognitive impairment. Published by Elsevier Inc.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据